India suspends import/manufacture of rosiglitazone and its FDCs
This article was originally published in Scrip
Executive Summary
India has suspended the importation and manufacture of the diabetes drug, rosiglitazone, following recent international regulatory action against GlaxoSmithKline's Avandia (rosiglitazone) in view of its link to cardiovascular safety issues.